Phase II Evaluation of Mitozolomide in Ovarian Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1988 Jan 1

PMID 3348943

Citations 5

Authors

M Harding

D Northcott

J Smyth

N S Stuart

J A Green

E NEWLANDS

Affiliations

Soon will be listed here.

Citing Articles

Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers.

Huseman E, Lo A, Fedorova O, Elia J, Gueble S, Lin K J Am Chem Soc. 2024; 146(27):18241-18252.

PMID: 38815248 PMC: 11409917. DOI: 10.1021/jacs.3c06483.

Temozolomide and Other Alkylating Agents in Glioblastoma Therapy.

Strobel H, Baisch T, Fitzel R, Schilberg K, Siegelin M, Karpel-Massler G Biomedicines. 2019; 7(3).

PMID: 31505812 PMC: 6783999. DOI: 10.3390/biomedicines7030069.

Relationship between the pharmacokinetics and toxicity of mitozolomide.

Kerr D, Slack J, Secrett P, Stevens M, Blackledge G, Bradley C Cancer Chemother Pharmacol. 1990; 25(5):352-4.

PMID: 2306796 DOI: 10.1007/BF00686236.

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Newlands E, Blackledge G, Slack J, Rustin G, Smith D, Stuart N Br J Cancer. 1992; 65(2):287-91.

PMID: 1739631 PMC: 1977719. DOI: 10.1038/bjc.1992.57.

A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.

McKeage M, Dady P, Clear M, Macdonald A Cancer Chemother Pharmacol. 1992; 29(3):201-6.

PMID: 1733552 DOI: 10.1007/BF00686253.

References

Stevens M, Hickman J, Stone R, Gibson N, Baig G, Lunt E . Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent. J Med Chem. 1984; 27(2):196-201. DOI: 10.1021/jm00368a016. View

RICHARDSON G, Scully R, Nikrui N, NELSON Jr J . Common epithelial cancer of the ovary (2). N Engl J Med. 1985; 312(8):474-83. DOI: 10.1056/NEJM198502213120804. View

Erba E, Pepe S, Ubezio P, Lorico A, Morasca L, Mangioni C . Mitozolomide activity on human cancer cells in vitro. Br J Cancer. 1986; 54(6):925-32. PMC: 2001596. DOI: 10.1038/bjc.1986.263. View

Newlands E, Blackledge G, Slack J, Goddard C, Brindley C, Holden L . Phase I clinical trial of mitozolomide. Cancer Treat Rep. 1985; 69(7-8):801-5. View

Hickman J, Stevens M, Gibson N, Langdon S, Fizames C, Lavelle F . Experimental antitumor activity against murine tumor model systems of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one (mitozolomide), a novel broad-spectrum agent. Cancer Res. 1985; 45(7):3008-13. View